drugset
drugset / Trial / NCT05076422

A Study to Test How Well Men Tolerate Different Doses of BI 3006337

NCT05076422 ↗

Phase 1 Completed 80 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics of BI 3006337 in healthy male subjects following subcutaneous administration of single-rising doses.

Timeline

Start
2021-10-18
Primary completion
2023-03-03
Completion
2023-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3006337 Unknown 0.2 mg Subcutaneous
Subject BI 3006337 Unknown 0.5 mg Subcutaneous
Subject BI 3006337 Unknown 1 mg Subcutaneous
Subject BI 3006337 Unknown 2 mg Subcutaneous
Subject BI 3006337 Unknown 4 mg Subcutaneous
Subject BI 3006337 Unknown 8 mg Subcutaneous
Subject BI 3006337 Unknown 15 mg Subcutaneous
Subject BI 3006337 Unknown 30 mg Subcutaneous
Subject BI 3006337 Unknown 50 mg Subcutaneous
Subject BI 3006337 Unknown 100 mg Subcutaneous
Subject BI 3006337 Unknown 150 mg Subcutaneous

Indications

No indication recorded.